托瑞米芬

Description

Toremifene · CAS 89778-26-7 · C26H28ClNO. UNII 7NFE54O27T. Melting Point: 108-110 °C; Melting Point: 108 - 110 °C; Solubility: 4.09e-04 g/L.

Identification

CAS Registry Number	89778-26-7
PubChem CID	3005573
Molecular formula	C26H28ClNO
IUPAC name	2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
UNII (FDA)	7NFE54O27T

Computed Descriptors

Molecular Weight	406.0
XLogP3	7.2
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	9
Exact Mass	405.1859422
Monoisotopic Mass	405.1859422
Topological Polar Surface Area	12.5
Heavy Atom Count	29
Formal Charge	0

Physical & Chemical Properties

Melting Point	108-110 °C
Melting Point	108 - 110 °C
Solubility	4.09e-04 g/L
LogP	6.8

Physical description & handling notes

• Solid
• 203.3 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID2021367]
• 197.7 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID2021367]

Documented Uses

• For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.
• Toremifene is a nonsteroidal antiestrogen that is used in the treatment of estrogen receptor positive breast cancer. Long term toremifene therapy has been associated with development of fatty liver, steatohepatitis, cirrhosis, and rare instances of clinically apparent acute liver injury.
• Toremifene citrate is approved to treat:
• • Breast cancer that has spread to other parts of the body. It is used in postmenopausal women whose cancer is estrogen receptor positive (ER+) or when it is not known if the cancer is ER+ or estrogen receptor negative (ER-).
• Avoid grapefruit products. Grapefruit inhibits CYP3A4 and therefore, may elevate toremifene serum levels.
• A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)

Synonyms

toremifene; 89778-26-7; Acapodene; Farestone; Toremifeno; Toremifenum; Chlortamoxifen; Toremiphene; GTx-006; 7NFE54O27T; J33.157K; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; CHEBI:9635; DTXSID3023689; (2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine; Ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-

Frequently Asked Questions

What are the CAS number and molecular formula of Toremifene?

CAS 89778-26-7; molecular formula C26H28ClNO; molecular weight — g/mol.

What other names is Toremifene known by?

toremifene, 89778-26-7, Acapodene, Farestone, Toremifeno, Toremifenum.

What are the key physical properties of Toremifene?

Melting Point: 108-110 °C; Melting Point: 108 - 110 °C; Solubility: 4.09e-04 g/L; LogP: 6.8.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.